Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer

Fletcher NM, Nicole M Fletcher, Jiang Z, Zhongliang Jiang, Ali-Fehmi R, Rouba Ali-Fehmi, Nancy K Levin, Levin NK, Jimmy Belotte, Belotte J, Michael A Tainsky, Tainsky MA, Michael P. Diamond, Husam M. Abu‐Soud, Husam M Abu-Soud, Ghassan M. Saed
Cancer biomarkers : section A of Disease markers · 2011 · vol. 10(6) , pp. 267–75 · doi:10.3233/cbm-2012-0255 · PMID:22820082 · PMC13016252
Other OA: closed
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-08 ⓘ

This study found that elevated serum free iron levels, and to a lesser extent MPO, are associated with early-stage ovarian cancer compared to non-cancerous conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-22 · read from full text ⓘ

This study investigated the potential of serum myeloperoxidase and free iron as biomarkers for the early detection and prognosis of ovarian cancer. Researchers analyzed serum and tissue samples from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls using ELISA and VITROS assays. The results demonstrated significantly higher levels of free iron in serum and tissues for stages II–IV compared to stage I, while serum free iron was also elevated in early-stage cancer relative to non-cancer groups despite overlapping myeloperoxidase levels with inflammatory conditions. These findings indicate that combining these two markers may improve diagnostic accuracy for identifying ovarian cancer at earlier stages. This paper is centrally about ovarian cancer; it does not explicitly discuss endometriosis or adenomyosis, but was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer. METHODS: Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant). RESULTS: There was a significant increase in the level of free iron in serum and tissues obtained from stages II-IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups. CONCLUSIONS: Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.
Full text 1,398 characters · extracted from oa-html · 5 sections · click to expand

Abstract

Objective: The study sought to identify whether a relationship exists between serum myeloperoxidase (MPO) and free iron with stages of ovarian cancer.

Methods

Serum and tissue samples were collected from women with stages I through IV ovarian cancer, benign gynecologic conditions, inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS Fe Slide assays were used to measure serum and tissue MPO and free iron levels, respectively. Data were analyzed with a one-way ANOVA with post-hoc comparisons (p < 0.05 considered significant).

Results

There was a significant increase in the level of free iron in serum and tissues obtained from stages II–IV as compared to early-stage (stage I) ovarian cancer. There was an overlap between early-stage and inflammation serum MPO levels, however serum free iron levels were significantly higher in early-stage. There was no significant change in serum free iron levels between non-cancer groups. In contrast, there was a significant increase in serum free iron levels in early-stage as compared to non-cancer groups.

Conclusions

Collectively, these findings clearly indicate a role for the combination of serum MPO and free iron as biomarkers for early detection and prognosis of ovarian cancer.

Keywords

Myeloperoxidase, free iron, ovarian cancer, biomarkers Full Text The Full Text of this article is available as a PDF (287.3 KB).

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Biomarkers, Tumor Iron Ovarian Neoplasms Ovarian Neoplasms Peroxidase Analysis of Variance Biomarkers, Tumor Biomarkers, Tumor Case-Control Studies Early Detection of Cancer Female Humans Iron Middle Aged Neoplasm Staging Ovarian Neoplasms Ovarian Neoplasms Peroxidase Peroxidase Prognosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:10:37.302907+00:00
unpaywall
last seen: 2026-10-30T06:30:42.975179+00:00